Igene Biotechnology Stock Fundamentals
Igene Biotechnology fundamentals help investors to digest information that contributes to Igene Biotechnology's financial success or failures. It also enables traders to predict the movement of Igene Pink Sheet. The fundamental analysis module provides a way to measure Igene Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Igene Biotechnology pink sheet.
Igene |
Igene Biotechnology Company Current Valuation Analysis
Igene Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Igene Biotechnology Current Valuation | 1.1 M |
Most of Igene Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Igene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Igene Biotechnology has a Current Valuation of 1.1 M. This is 99.99% lower than that of the Chemicals sector and 99.99% lower than that of the Materials industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Igene Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Igene Biotechnology's current stock value. Our valuation model uses many indicators to compare Igene Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Igene Biotechnology competition to find correlations between indicators driving Igene Biotechnology's intrinsic value. More Info.Igene Biotechnology is rated third overall in return on asset category among its peers. It is rated fourth overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Igene Biotechnology's earnings, one of the primary drivers of an investment's value.Igene Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Igene Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Igene Biotechnology could also be used in its relative valuation, which is a method of valuing Igene Biotechnology by comparing valuation metrics of similar companies.Igene Biotechnology is currently under evaluation in current valuation category among its peers.
Igene Fundamentals
| Return On Asset | -0.0821 | |||
| Operating Margin | (124.22) % | |||
| Current Valuation | 1.1 M | |||
| Shares Outstanding | 1.57 B | |||
| Shares Owned By Institutions | 0.47 % | |||
| Price To Earning | (0.10) X | |||
| Price To Sales | 2.28 X | |||
| Revenue | 3.96 M | |||
| Gross Profit | 1.02 M | |||
| EBITDA | (426.98 K) | |||
| Net Income | (140.75 K) | |||
| Cash And Equivalents | 269.29 K | |||
| Current Ratio | 1.15 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (97.05 K) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 18 | |||
| Beta | -2.8 | |||
| Market Capitalization | 10.96 K | |||
| Total Asset | 4.76 M | |||
| Retained Earnings | (54.86 M) | |||
| Working Capital | 312 K | |||
| Current Asset | 2.44 M | |||
| Current Liabilities | 2.13 M | |||
| Z Score | -15.4 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 4.76 M |
About Igene Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Igene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Igene Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Igene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland. IGENE BIOTECHNOLOGY operates under Agricultural Inputs classification in the United States and is traded on PNK Exchange. It employs 18 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Igene Pink Sheet
Igene Biotechnology financial ratios help investors to determine whether Igene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Igene with respect to the benefits of owning Igene Biotechnology security.